

ESMO 2022 INDUSTRY SATELLITE SYMPOSIUM
SUNDAY 11 SEPTEMBER 2022, 18:30–20:00 CEST
7.3.T - TOULOUSE AUDITORIUM
HALL 7, LEVEL 7.3
PARIS EXPO PORTE DE VERSAILLES
PARIS, FRANCE



FROM CLINICAL TRIAL TO REAL-WORLD EVIDENCE:

EVERYDAY PRACTICE WITH *MET*_{ex14} INHIBITORS IN NSCLC



Alexis Cortot
Centre Hospitalier
Régional Universitaire
de Lille
(Lille, France)



Keith Kerr
Aberdeen University
Medical School
(Aberdeen, UK)



Maximilian Hochmair
Klinik Floridsdorf
(Vienna, Austria)

Chair: Alexis Cortot

- 18:30–18:33 **Welcome and introduction**
Alexis Cortot (France)
- 18:33–18:48 **Identifying *MET*-dysregulated NSCLC: the path to diagnosis**
Keith Kerr (UK)
- 18:48–19:03 **Expanding treatment options for patients with *MET* exon 14 skipping mutation in NSCLC**
Alexis Cortot (France)
- 19:03–19:28 ***MET* inhibition for patients with *MET*_{ex14} NSCLC in the real world**
All, moderated by Alexis Cortot (France)
- 19:28–19:48 ***MET* inhibition: experience from clinical trials and beyond**
Maximilian Hochmair (Austria)
- 19:48–19:58 **Q&A with the audience**
All, moderated by Alexis Cortot (France)
- 19:58–20:00 **Meeting closure**
Alexis Cortot (France)

This program is intended to foster scientific education and exchange and will not be promotional in language, appearance, or intent. Scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside the USA, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations.

